Degenerative Disease Articles & Analysis
73 news found
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, ...
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. ...
This platform is applicable across a wide scope of disease indications. It combines a compounding database mapping secreted proteins to specific diseases, an in silico screening technology, wetlab screening in primary human cell and animal models, and protein engineering capabilities creating a fully integrated approach for accelerating the development of ...
” About Retinitis Pigmentosa Retinitis pigmentosa (RP), is a heterogeneous group of genetic diseases that cause retinal degeneration leading to near or complete blindness for most patients. The severe loss of photoreceptor cells that occurs in this genetic degenerative disease leads to partial or complete blindness. At present, no ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San ...
These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. ...
Besides their allergy program, ANGANY is also working in developing other immunotherapy applications including degenerative disease and oncology for both human and veterinary indications. ...
Excite Medical continues to support the chiropractic community by providing the most advanced alternative to surgery for herniated discs, bulging discs, and degenerative disc disease. About Excite Medical Excite Medical is a global leader in the spinal decompression field. ...
We remain committed to leading the next evolution of cellular therapies for the treatment of cancer, immunological and degenerative diseases using our highly proprietary placental-derived cell therapy ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and ...
These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic ...
” Excite Medical continues to support the chiropractic community by providing the most advanced alternative to surgery for herniated discs, bulging discs and degenerative disc disease. About Excite Medical: Excite Medical is determined to make a global impact by reducing the number of unnecessary spine surgeries taking place around the world. ...
(Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and ...
Dry Eye Syndrome is a chronic disease that affects the productivity and quality of life of 1.52 billion people worldwide [1]. The COVID-19 pandemic has further exacerbated the problem, as prolonged time in front of screens is a risk factor for the disease. Other risk factors include aging, eye surgeries, dry environments, long-term wearing of contact lenses, ...
As such, we believe we are well-positioned to continue executing our business strategy and developing cellular therapies for cancer, infectious and degenerative diseases that leverage our proprietary placental-based technology ...
Michael Kjær Jacobsen, at the Center for Spine Surgery and Research in Southern Denmark, led the double-blind, prospective, randomized study in more than 100 patients (60 years or older). Participants suffered from degenerative spondylolisthesis and underwent decompression and non-instrumented posterolateral fusion surgery, randomized to either i-FACTOR bone graft or fresh ...
Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). The FDA’s Breakthrough Device designation is designed to expedite the development and review of medical devices that are intended to treat serious or life-threatening ...
To slow down the ageing of tissues in these three so-called ‘degenerative’ diseases, we have developed a unique technology for producing chitosan, a polymer from the polysaccharide family, from mushrooms. ...
About the DRX9000: When compared to minimally-invasive and invasive spinal procedures, the DRX9000 is the world’s most advanced and safest option to treat herniated discs, bulging discs, and degenerative disc disease. Patients suffering from low back pain, sciatica, and neuropathy caused by those disc conditions have a profound success rate in resolving ...
“These data, though uncontrolled, offer the promising demonstration that OpRegen may be able to impact GA disease progression in a clinically meaningful manner, particularly when delivered on-target and in earlier disease, in patients afflicted with what was previously thought to be an inevitably progressive disease,” stated Dr. ...